MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
April 13 2023 - 7:00AM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the
“Company” or "MindMed"), a clinical-stage biopharmaceutical company
developing novel product candidates to treat brain health
disorders, today announced the appointment of Mark R. Sullivan,
effective today, as Chief Legal Officer and Corporate
Secretary.
“We are very excited to welcome Mark to our management team.
Mark brings tremendous legal and public company life sciences
expertise and will be a strong addition to our executive team. We
believe Mark’s experience, insights and guidance will prove
invaluable as MindMed progresses to the next stage of its
evolution. I look forward to working closely with Mark during this
transformative time for the company,” said Robert Barrow, Chief
Executive Officer and Director of MindMed.
“This is an exciting time to be joining the Company at this
pivotal juncture as it advances towards several key inflection
points for its pipeline,” said Mr. Sullivan. “I look forward to
working with the MindMed management team as the Company continues
advancing its clinical programs and pursues commercial capabilities
to fulfill its mission of improving the lives of the millions of
individuals suffering from brain health disorders.”
Mr. Sullivan is an experienced public company General Counsel
and Corporate Secretary, with extensive expertise and demonstrated
success in the areas of SEC reporting, financing, corporate
governance and compliance, mergers and acquisitions, intellectual
property, litigation management and business development. Prior to
joining the Company, Mr. Sullivan was the General Counsel and
Corporate Secretary of Sesen Bio, a biopharmaceutical company
(prior to its merger with Carisma Therapeutics) (NASDAQ: CARM),
from August 2019 to April 2023. Before that, he served as a private
consultant to numerous life sciences companies. Previously, he
served as the General Counsel, Chief Compliance Officer and
Secretary of MModal Inc. (Nasdaq: MODL), formerly MedQuist, Inc., a
leading healthcare IT company, until it was taken private by One
Equity Partners, the private investment arm of JP Morgan Chase
& Co. Prior to joining MModal, Mr. Sullivan was in private
practice with Pepper Hamilton LLP and Drinker Biddle & Reath
LLP. Mr. Sullivan received a B.A. from the University of
Pennsylvania and a J.D. from the Rutgers University School of
Law.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding anticipated
upcoming milestones, trials and studies, results and timing of
clinical trials. There are numerous risks and uncertainties that
could cause actual results and the Company’s plans and objectives
to differ materially from those expressed in the forward-looking
information, including history of negative cash flows; limited
operating history; incurrence of future losses; availability of
additional capital; lack of product revenue; compliance with laws
and regulations; difficulty associated with research and
development; risks associated with clinical trials or studies;
heightened regulatory scrutiny; early stage product development;
clinical trial risks; regulatory approval processes; novelty of the
psychedelic inspired medicines industry; as well as those risk
factors discussed or referred to herein and the risks described in
the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2022 under headings such as “Special Note Regarding
Forward-Looking Statements,” and “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” and other filings and furnishings made by the Company
with the securities regulatory authorities in all provinces and
territories of Canada which are available under the Company’s
profile on SEDAR at www.sedar.com and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov. Except as required by
law, the Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230413005290/en/
For Media & Investor Inquiries, please contact:
Maxim Jacobs, CFA Vice President, Investor Relations and
Corporate Communications Mind Medicine (MindMed) Inc. ir@mindmed.co
media@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From May 2024 to Jun 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Jun 2023 to Jun 2024